Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neuroblastoma 2Solid Tumors 1Solid Tumor 1Relapsed Solid Tumors 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1

Interventions

Cyclophosphamide 53Etoposide 33Temozolomide 28Irinotecan 28Melphalan 25Filgrastim 25Topotecan 24Carboplatin 243-Iodobenzylguanidine 23Isotretinoin 20Granulocyte Colony-Stimulating Factor 17sargramostim 16humanized 3F8 anti-GD2 monoclonal antibody 16dinutuximab 16Granulocyte-Macrophage Colony-Stimulating Factor 16fludarabine 15Vincristine 15Doxorubicin 15Cisplatin 15Peripheral Blood Stem Cell Transplantation 14Interleukin-2 14Busulfan 13naxitamab 12Thiotepa 12Radiotherapy 12aldesleukin 11fludarabine phosphate 10etoposide phosphate 8Mesna 8Ifosfamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neuroblastoma × Cefixime × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

NCT00644696 2017-07-06

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

University of Michigan Rogel Cancer Center

Phase 1 Completed
18 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡